Desoxypipradrol

Standard Drug Panel Inclusion

Desoxypipradrol (2-DPMP) is a pipradrol-derivative stimulant that is not detected on standard immunoassay drug screens. Its diphenylmethyl piperidine structure is distinct from amphetamines, and no cross-reactivity with standard immunoassays is expected. No extended panels include pipradrol-class compounds.

Urine Detection

Desoxypipradrol has an exceptionally long duration of action and correspondingly extended detection window. It can be detected in urine for approximately 3 to 7 days or longer after a single dose, owing to its long elimination half-life. Metabolism involves hydroxylation and conjugation, but a significant portion is excreted unchanged. Standard immunoassays do not detect desoxypipradrol.

Blood and Saliva Detection

Due to its long half-life, desoxypipradrol can be detected in blood for 48 to 96 hours or more after ingestion. This extended blood detection window is unusual among stimulants and reflects the compound's slow elimination kinetics. Oral fluid detection may persist for a similar duration.

Hair Follicle Detection

Hair analysis for desoxypipradrol requires specialized LC-MS/MS methods not available through standard commercial laboratories. The long systemic exposure per dose may result in relatively higher hair incorporation compared to shorter-acting stimulants.

Confirmatory Testing

LC-MS/MS and GC-MS can identify desoxypipradrol based on its distinctive diphenylmethyl piperidine structure. The compound's high molecular weight and characteristic fragmentation pattern make it readily distinguishable from amphetamines, cathinones, and other stimulant classes.

Reagent Testing

Marquis reagent shows no reaction or a faint color change with desoxypipradrol. Mecke and Mandelin reagents similarly show minimal reactions. The lack of characteristic reagent responses is consistent with the pipradrol structural class and helps rule out amphetamines and cathinones.

Consider Not Using This Compound

The harm reduction recommendation that applies to desoxypipradrol more than almost any other research chemical stimulant is: genuinely consider whether use is appropriate at all. The risk-to-benefit profile is severely unfavorable for any recreational or functional use: the duration cannot be controlled, the experience cannot be reliably ended, and the consequences of unexpected multi-day stimulation (including psychiatric crisis) are serious.

If Use Occurs: Microdose Protocol

If desoxypipradrol is used:

• Doses must be measured in micrograms or very low milligrams — community reports suggest active doses as low as 2–5 mg, and even these produce multi-day effects
• Use a precision milligram scale; 0.001g minimum resolution
• Consider using a 1:10 or 1:100 solution dilution to improve dose precision
• Have no obligations for 72+ hours — work, driving, childcare, and social commitments must be completely clear

Never Redose

Under any circumstances, do not administer a second dose while any effects from the first dose are perceptible. The first dose may not fully express for hours after ingestion.

Harm Reduction During Extended Effects

• Maintain hydration
• Eat small amounts even if appetite is suppressed — hypoglycemia worsens cognitive impairment
• Have a trusted person who can monitor your wellbeing
• If psychiatric symptoms develop (paranoia, hallucinations, dissociation), seek medical evaluation — describe the substance and duration of effects clearly

Context from Reddit

The Reddit discussion thread on "2-DPMP (desoxypipradrol), Diphenylprolinol (D2PM) and pipradrol discussion" reflects a community that has documented extensive adverse experiences and uses such threads as harm reduction resources. The general consensus is extreme caution.

Duration-Mediated Toxicity: Primary Risk

The primary clinical risk of desoxypipradrol is not acute pharmacological toxicity in the traditional sense, but the consequences of forced multi-day wakefulness:

• Severe sleep deprivation: 24–72 hours of enforced wakefulness produces profound cognitive impairment, hallucinations (stimulant psychosis), immune suppression, and cardiovascular stress
• Stimulant psychosis: Multiple case reports in UK medical literature document acute psychotic episodes requiring hospitalization following 2-DPMP use, directly attributable to the prolonged stimulation period
• Inability to "redose safely": Unlike other stimulants where timing manages the experience, desoxypipradrol's duration makes any redosing during the initial dose's duration period catastrophically dangerous

UK Hospital Experience

The emergence of 2-DPMP in UK "legal high" products (marketed as "Ivory Wave" and similar) in 2010–2012 generated significant Emergency Department data. Case series documented psychosis, severe agitation, self-harm behavior, and cardiac complications requiring hospitalization for multi-day duration symptoms. This real-world data established the compound's clinical danger profile.

Cardiovascular Risk

As a potent NDRI, sustained norepinephrine elevation over 24–72 hours produces prolonged cardiovascular stress — tachycardia, hypertension — with meaningful risk for adverse events particularly in those with cardiac conditions.

No Antagonist

There is no specific antidote or mechanism to accelerate clearance of desoxypipradrol. Supportive care is the only treatment for adverse reactions. Benzodiazepines can partially address anxiety and agitation but cannot reverse the stimulant effect.

• China: As of October 2015, 2-DPMP is a controlled substance in China.

• Germany: Desoxypipradrol is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.

• Russia: Deoxypipradol is entered in the Schedule I prohibited substance as (Пиперидин-2-ил)дифенилметан.

• Switzerland: Desoxypipradol is not controlled under Buchstabe A, B, C and D. It could be considered legal.

• United Kingdom: As of November 4, 2010, the UK Home Office announced a ban on the importation of 2-DPMP, following a recommendation from the ACMD. Prior to the import ban, desoxypipradrol was sold as a 'legal high' in several products. Its use lead to several Emergency Department visits which prompted the UK government to commission a review from the ACMD. The Advisory Council on the Misuse of Drugs stated in their report that: "there are serious harms associated with 2-DPMP... typically prolonged agitation (lasting up to 5 days after drug use which is sometimes severe, requiring physical restraint), paranoia, hallucinations and myoclonus (muscle spasms/twitches)." 2-DPMP was due to become a class B drug on March 28, 2012, but the bill was scrapped as two steroids deemed not to be abusable were included in the bill but were later recommended to remain uncontrolled. There was a new discussion about its fate on April 23, 2012, where it was decided that the bill would be rewritten and 2-DPMP would still be banned. It was also decided that the bill would be a blanket ban of related chemicals. Desoxypipradrol was eventually made a class B drug and placed in Schedule I on June 13, 2012. There were no recorded deaths from the drug between the banning of its import and the banning of its possession. "Esters and ethers of pipradrol" were controlled with the same amendment as class C drugs.

• United States: Desoxypipradrol is unscheduled in the United States, and thus legal to possess and import. However, it is an analog of pipradol which is a Schedule IV Controlled Substance.

• Responsible use

• Stimulants

• Research chemical

• Desoxypipradrol (Wikipedia)

• Desoxypipradrol (Isomer Design)